EN DE
Watch Spero Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Spero Therapeutics Inc (SPRO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Spero Therapeutics Inc stock $2.50, price $1.03, upside +142.7%, quality 77 out of 100. Rating: strongly undervalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

ST Spero Therapeutics Inc logo Some data Nov 8, 2026

Spero Therapeutics Inc

SPRO · US
Undervalued, but in a downtrend

The stock costs 59% less than our calculation considers fair.

Fair value $2.50 · Strongly undervalued
Quality 77/100
Solidly profitable · 15.7% net margin (TTM)
Low debt
Generates free cash flow over the last twelve months
Ranks above peers (11/12)
Even on cautious assumptions the value is 83% above the price ($1.88).
Mixed Growth (revenue 5y +44.9 %/yr in USD)
Moderate moat 64/100 · thin data
Some data
Watch Spero Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.51 $0.5600 Fair Value $2.50 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $0.5600 – $19.51 · fair‑value band $1.88 – $3.13 · the $1.03 price screens below the $2.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Spero Therapeutics in your weekly email

Every Wednesday you see whether Spero Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Show moreShow less

The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.

Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Spero Therapeutics Inc (SPRO) currently trades at $1.03, while our model-based Fair Value estimate is $2.50, implying the stock looks roughly 59% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $4.36 per share, and 7 of the 9 models we run sit above the $1.03 price.

Bear case: the Economic Profit group reads lowest at $0.9600, and 2 of the 9 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $1.88 (bear) to $3.13 (bull), the price of $1.03 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Spero Therapeutics Inc reported revenue of $59.6M in FY2025 versus $3.1M in FY2021, a compound +109.9%/yr. Reported net income was $8.6M in FY2025.

Key figures

Market cap $61.1M Micro · P/E ratio 7.9 · P/S ratio 1.30 · EPS (TTM) $0.1300 · Net margin 15.7% · Return on equity 19.2% · Return on assets (EBIT) −28.0% (5-year average) · Operating margin 14.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 143%, SPRO screens cheaper than that median.

Fair Value models

Bear $1.88 Fair Value $2.50 Bull $3.13
Price $1.03 · Upside +142.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1115 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income $0.8500 $0.9600 $1.21 71
Growth-Adj P/E $3.05 $4.36 $5.67 67
Graham-Dodd $1.00 $6.98 $9.80 63
All 9 models by family
Earnings-Based
Graham-Dodd $1.00 $6.98 $9.80 63
Lynch FV $2.25 $3.21 $4.17 61
PEG = 1.0 $2.25 $3.21 $4.17 57
Multiples
P/E Multiple $2.43 $3.24 $4.05 63
P/S Multiple $1.88 $2.50 $3.13 58
P/B Multiple $0.9200 $1.22 $1.53 55
Asset-Based
NCAV (Graham) $0.6500 $0.9900 $1.23 55
Economic Profit
Residual Income $0.8500 $0.9600 $1.21 71
Growth Earnings
Growth-Adj P/E $3.05 $4.36 $5.67 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 77/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 71
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 12
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleEsther RajaveluOfficer3× since Feb 2, 2026: 131,599 shares, avg. $2.37$311,409May 4, 2026
  • SaleTimothy KeutzerChief Operating Officer2× since Feb 2, 2026: 65,238 shares, avg. $2.23$145,193Feb 6, 2026

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+24.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+77.8%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−34.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−34.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−848% → 0%

Watch SPRO, get fair value alerts →

Compare Spero Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside +142.7% · Top 25%
Profitability
Return on equity (12 months) 19.2% · Top 25%
Return on assets 12.4% · Top 25%
Net margin (12 months) 15.7% · Above median
Operating margin (12 months) 14.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) −95.6% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 7.9× · Cheapest 25%
P/B 1.03× · Cheapest 25%
P/S (12 months) 1.30× · Cheapest 25%
EV/EBITDA 2.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)77 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs SPRO
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs SPRO
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs SPRO
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs SPRO
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs SPRO
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs SPRO
argenx SE ARGX $927.21 $908.40 −2% vs SPRO
CSL Limited CSL A$200.77 A$183.04 −9% vs SPRO
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs SPRO
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs SPRO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Spero Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Spero Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/SPRO

Frequently asked questions

Is Spero Therapeutics Inc (SPRO) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.50 versus a price of $1.03, about +143% upside (undervalued).
What is the fair value of SPRO?
Our model-based fair value for Spero Therapeutics Inc is $2.50 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.03.
What is the quality score of SPRO?
Spero Therapeutics Inc has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Spero Therapeutics Inc (SPRO)?
Our model-based price target is the fair value of $2.50 (as of Nov 8, 2026) from 9 valuation models. Cautious scenario $1.88, optimistic scenario $3.13. It is a calculation from audited fundamentals, not an analyst target.
What is the Spero Therapeutics Inc stock forecast for 2026?
Our models put fair value at $2.50, about +143% upside versus a price of $1.03 (undervalued). Cautious scenario $1.88, optimistic scenario $3.13. The calculation is refreshed regularly with new filings.
What is the revenue of Spero Therapeutics Inc (SPRO)?
Spero Therapeutics Inc reported trailing-twelve-month revenue of about $47.0M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Spero Therapeutics Inc (SPRO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Spero Therapeutics Inc it is $2.50 per share (as of Nov 8, 2026), against a price of $1.03. It is the blended result of 9 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Spero Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SPRO trades below its calculated fair value: price $1.03, fair value $2.50, a gap of about +143% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPRO?
No. The price is what the market pays today ($1.03); the fair value is what the company's own numbers justify ($2.50). For Spero Therapeutics Inc the two are $1.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Spero Therapeutics Inc worth?
The market values Spero Therapeutics Inc at about $61.1M (market capitalisation, as of Nov 8, 2026). Per share that is $1.03; our models calculate a fair value of $2.50 per share.
What do the bullish and bearish scenarios say about SPRO?
Our models span a range for Spero Therapeutics Inc: cautious scenario $1.88, base $2.50, optimistic $3.13 per share (as of Nov 8, 2026, price $1.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SPRO?
Spero Therapeutics Inc trades at a price-to-earnings ratio of 7.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.50 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 6.4 (reported for FY2025: 6.9). Other multiples: P/B 1.0, P/S 1.3, EV/EBITDA 2.9.
How solid is the balance sheet of Spero Therapeutics Inc (SPRO)?
Balance-sheet figures for Spero Therapeutics Inc (as of Nov 8, 2026): return on equity 19.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is SPRO from its 52-week high?
Spero Therapeutics Inc trades at $1.03, about 65% below its 52-week high of $2.98 and 1% above the low of $1.02 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.50 is for.
Which stocks are comparable to Spero Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Spero Therapeutics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $1.03, calculated fair value $2.50 (+143%), Quality Score 77/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPRO calculated?
We run Spero Therapeutics Inc through 9 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $2.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Spero Therapeutics Inc currently trades 59% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Spero Therapeutics Inc (SPRO)?
The closing price on Nov 6, 2026 was $1.03. Our model-based fair value is $2.50, about +143% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Spero Therapeutics Inc right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($1.88). The market is more pessimistic than our downside scenario.

Key figures of Spero Therapeutics Inc

How large is the market capitalisation of Spero Therapeutics Inc (SPRO)?
The market capitalisation of Spero Therapeutics Inc is $61.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Spero Therapeutics Inc (SPRO)?
The price-to-sales ratio of Spero Therapeutics Inc is 1.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Spero Therapeutics Inc (SPRO)?
Earnings per share at Spero Therapeutics Inc are $0.1300 (price ÷ EPS = P/E 7.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Spero Therapeutics Inc (SPRO)?
The net margin of Spero Therapeutics Inc is 15.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Spero Therapeutics Inc (SPRO)?
The return on equity (ROE) of Spero Therapeutics Inc is 19.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Spero Therapeutics Inc (SPRO)?
On an EBIT basis the return on assets of Spero Therapeutics Inc is −28.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Spero Therapeutics Inc (SPRO)?
The operating margin of Spero Therapeutics Inc is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Spero Therapeutics Inc (SPRO)?
Revenue at Spero Therapeutics Inc is growing −95.6% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Spero Therapeutics Inc (SPRO)?
Earnings per share at Spero Therapeutics Inc are growing +75.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Spero Therapeutics Inc (SPRO) generate?
The free cash flow of Spero Therapeutics Inc is −$12.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Spero Therapeutics Inc (SPRO) hold?
Spero Therapeutics Inc holds more cash than debt, $37.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Spero Therapeutics Inc in the live analysis

One click puts Spero Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.